论文部分内容阅读
目的:研究重组人脑钠肽(rhBNP)治疗急性心肌梗塞伴急性左心衰的临床疗效。方法:选取30例急性心肌梗塞伴急性左心衰患者,分别观察患者用药治疗前后的15min、lh、3h、24h、72h的肺毛细血管楔压(PCWP),心脏排血指数(CI),及血压等四大生命体征及气促等症状改善情况。结果:在常规治疗基础上,加用重组人脑钠肽治疗后,患者各时间段的平均肺毛细血管楔压(PCWP)明显的降低;心脏排血指数(CI)明显增加,血压、心率、呼吸等均下降到正常平稳状态,24h的尿量也明显增加,心慌、气促等症状均得到了明显改善,均P<0.05。结论:rhBNP能有效改善DHF的临床症状和体征,改善心肌细胞功能,改善患者的生活质量,对DHF患者的临床治疗有重要的价值。
Objective: To study the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) in the treatment of acute myocardial infarction with acute left heart failure. Methods: Thirty patients with acute myocardial infarction and acute left heart failure were enrolled in this study. Pulmonary capillary wedge pressure (PCWP), cardiac output index (CI) and cardiac output index (CI) at 15min, lh, 3h, 24h, Blood pressure and other four vital signs and symptoms such as shortness of breath to improve the situation. Results: The average pulmonary capillary wedge pressure (PCWP) decreased significantly at each time point after the addition of recombinant human brain natriuretic peptide, the cardiac output index (CI) increased significantly, and the blood pressure, heart rate, Respiration, etc. decreased to normal steady state, 24h urine output also increased significantly, palpitation, shortness of breath and other symptoms have been significantly improved, all P <0.05. Conclusion: rhBNP can effectively improve the clinical symptoms and signs of DHF, improve myocardial cell function, improve the quality of life of patients, and have an important value in the clinical treatment of DHF.